In support with this findings, ferroptosis inducers activate a prognostically adverse gene signature that includes HMGB1, linking its release to pathways of extracellular matrix remodeling and therapy resistance in aggressive breast cancer subtypes [179,180]. The gene discussed is HMGB1; the disease is breast cancer.